Redeye strengthens its confidence in the Episurf equity story, following the Capital Markets Day held last week. We have revised our long-term sales and are now closer aligned with the management’s targets. However, we want to see further clinical evidence and the first mark on top-line before we feel entitled to raise our estimates even further. Nonetheless, our revised estimates have a positive impact on all our fair values.
Read more and download the Research Update
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/